Does Rooibos Cardiometabolic Randomized Trial work?

Updated October 2026

Quick Answer

Rooibos Cardiometabolic Randomized Trial has evidence relevant to strength of evidence and what the studies can or cannot prove, but conclusions should stay close to the cited sources. One representative finding is: Elderly patients and patients with comorbidity disorders including pulmonary disease, cardiac disease, kidney disease, diabetes, and hypertension have been associated with greater mortality rates, suggesting highly susceptible and/or vulnerable groups within the infected population (,).

Key Takeaways

  • 01Elderly patients and patients with comorbidity disorders including pulmonary disease, cardiac disease, kidney disease, diabetes, and hypertension have been associated with greater mortality rates, suggesting highly susceptible and/or vulnerable groups within the infected population (,). [Sheik Abdul Naeem (2021)]
  • 02Consequently, it had been hypothesised that diabetes and hypertension treatment with ACE2-stimulating drugs increases the risk of developing severe and fatal COVID-19 (,). [Sheik Abdul Naeem (2021)]
  • 03Furthermore, there is some evidence to demonstrate that treatment with ACEIs or ARBs can decrease the severity of pulmonary injury by SARS-CoV-2, with preclinical data suggesting a potential mechanism of benefit (). [Sheik Abdul Naeem (2021)]
  • 04Lewnard and Lo, 2020 Fang et al., 2020 Emanuel et al., 2020 Shi et al., 2020 Patel and Verma, 2020 Rodriguez-Morales et al., 2020 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current Coronavirus disease 2019 (COVID-19) pandemic. [Sheik Abdul Naeem (2021)]
The current Migaku evidence database contains 1 reusable source document for Rooibos Cardiometabolic Randomized Trial. This answer focuses on strength of evidence and what the studies can or cannot prove. - Elderly patients and patients with comorbidity disorders including pulmonary disease, cardiac disease, kidney disease, diabetes, and hypertension have been associated with greater mortality rates, suggesting highly susceptible and/or vulnerable groups within the infected population (,). [Sheik Abdul Naeem (2021); evidence level 3] - Consequently, it had been hypothesised that diabetes and hypertension treatment with ACE2-stimulating drugs increases the risk of developing severe and fatal COVID-19 (,). [Sheik Abdul Naeem (2021); evidence level 3] - Furthermore, there is some evidence to demonstrate that treatment with ACEIs or ARBs can decrease the severity of pulmonary injury by SARS-CoV-2, with preclinical data suggesting a potential mechanism of benefit (). [Sheik Abdul Naeem (2021); evidence level 3] - Lewnard and Lo, 2020 Fang et al., 2020 Emanuel et al., 2020 Shi et al., 2020 Patel and Verma, 2020 Rodriguez-Morales et al., 2020 The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the current Coronavirus disease 2019 (COVID-19) pandemic. [Sheik Abdul Naeem (2021); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.

Sources

  1. Rooibos, a supportive role to play during the COVID-19 pandemic?